Why Choose Between Wegovy and Mounjaro at EverydayMeds?
Wegovy to Mounjaro: Understanding the Key Mechanism Differences
When comparing Wegovy to Mounjaro, the fundamental difference lies in their active ingredients and how they work in your body. Wegovy contains semaglutide, which is a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. Mounjaro, on the other hand, contains tirzepatide - a dual-action medication that targets both GIP and GLP-1 receptors, potentially offering a different approach to appetite regulation. Both prescription-only medicines require careful dose escalation under medical supervision, with Wegovy following a 5-step progression from 0.25mg to 2.4mg maintenance dose. Mounjaro uses a 6-step escalation from 2.5mg up to 15mg, though the dosing schedules and injection frequencies differ significantly between the two treatments.
Understanding these mechanism differences is crucial when transitioning from Wegovy to Mounjaro or deciding between them initially. Your prescriber will consider your individual response to GLP-1 therapy, any side effects experienced, and your specific weight management goals. At EverydayMeds, our clinical team can support both treatment pathways, ensuring you receive the most appropriate medication through our GPhC-registered pharmacy (#9012878). The choice between single-hormone (Wegovy) and dual-hormone (Mounjaro) approaches depends on various factors including your medical history and treatment response patterns.
Wegovy vs Mounjaro Pricing: Complete UK Cost Comparison
When evaluating the cost difference between Wegovy to Mounjaro options, EverydayMeds offers transparent pricing for both treatments. Wegovy single pens range from £79.99 for the 0.25mg starter dose to £209.99 for the 2.4mg maintenance dose, with new customers using code FIRST40 and returning customers using code DOSE25 at checkout. Our Wegovy bundles provide convenient multi-month supplies, such as the Intro Duo (0.25mg & 0.5mg pens) for £169.99 or the Ultimate Stability Trio (three 2.4mg pens) for £649.99. Mounjaro pricing follows a different structure due to its unique dosing regimen and higher dose concentrations. Both treatments require the same rigorous clinical assessment and prescriber review process, with identical next-day cold-chain delivery once approved.
The total cost comparison between Wegovy to Mounjaro depends on your individual dose escalation timeline and maintenance requirements. While initial starter doses may appear similar, the progression to maintenance dosing can vary significantly between the two treatments. EverydayMeds' bundle options for both medications help ensure consistent supply without repeated ordering, though we always recommend discussing the most cost-effective approach with your prescriber. Our 3-minute online assessment covers both treatment options, allowing our clinical team to provide personalised recommendations based on your specific circumstances and budget considerations.
Clinical Evidence: STEP Trials and Wegovy to Mounjaro Research
The clinical evidence supporting both Wegovy and Mounjaro comes from separate, robust trial programmes that cannot be directly compared due to different study designs and patient populations. In the STEP clinical trials, patients taking Wegovy alongside diet and exercise achieved an average weight loss of approximately 15% at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP programme also demonstrated sustained weight management benefits over 2 years and significant cardiovascular risk reduction in the SELECT trial.
Mounjaro's evidence base comes from the SURMOUNT trial series, which evaluated tirzepatide's dual-hormone approach in different patient populations. When considering switching from Wegovy to Mounjaro, patients should understand that both treatments require long-term commitment, with weight regain typically occurring if treatment is discontinued. The choice between these evidence-backed options should always be made in consultation with your prescriber, who can evaluate your individual response and determine the most appropriate treatment pathway based on clinical factors rather than trial comparisons alone.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy's active ingredient, semaglutide, functions as a GLP-1 receptor agonist that closely mimics your body's natural incretin hormones. When injected once weekly, it binds to GLP-1 receptors in your brain's appetite centres, particularly the hypothalamus, reducing hunger signals and enhancing feelings of fullness after meals. This mechanism also slows gastric emptying, meaning food stays in your stomach longer, contributing to prolonged satiety and reduced caloric intake. The medication may also reduce food cravings and the reward response associated with high-calorie foods, helping patients maintain their reduced-calorie diet more effectively. Unlike rapid-acting appetite suppressants, Wegovy's once-weekly dosing provides consistent hormone-level modulation throughout the week, supporting sustainable eating pattern changes. The dose escalation from 0.25mg to 2.4mg allows your body to gradually adapt to the medication while minimising potential gastrointestinal side effects during the adjustment period.
EverydayMeds Ordering Process: From Assessment to Delivery
Ordering either Wegovy or Mounjaro through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, which covers your medical history, current medications, and weight management goals. Our qualified prescribers review your assessment within standard 3 working days (or 24 hours with express service), ensuring both treatments are clinically appropriate for your circumstances. Once approved, your prescription-only medicine is dispensed from our GPhC-registered pharmacy (#9012878) and dispatched via next-day delivery using specialised cold-chain packaging to maintain the required 2-8°C temperature throughout transit. Our clinical team remains available for ongoing support throughout your treatment journey, whether you're starting Wegovy, considering Mounjaro, or discussing a potential switch between treatments. The entire process is designed to provide pharmaceutical-grade medication access with the convenience of home delivery while maintaining the highest standards of clinical oversight and patient safety.
Storage and Practical Considerations: Wegovy vs Mounjaro Differences
One significant practical advantage when comparing Wegovy to Mounjaro lies in storage flexibility and travel convenience. Wegovy pens can be stored at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both medications require initial refrigerated storage at 2-8°C before first use, but Wegovy's extended room temperature stability makes it more suitable for extended travel or situations where refrigeration access might be limited. The FlexTouch pen delivery system used by Wegovy is pre-filled and ready to use, with clear dose indication and ergonomic design for weekly self-injection. Both treatments follow strict dose escalation schedules that cannot be accelerated, requiring patients to progress through each dose level for the prescribed duration. This gradual increase helps minimise side effects while allowing your body to adapt to the medication's appetite-suppressing effects over the initial 12-16 weeks of treatment.
Switching from Wegovy to Mounjaro: Clinical Considerations
Patients considering transitioning from Wegovy to Mounjaro must do so under strict medical supervision, as both medications work on overlapping but distinct hormone pathways. The switch typically requires a washout period and careful monitoring to avoid overlapping effects or unexpected interactions between the GLP-1 and dual GIP+GLP-1 mechanisms. Your prescriber will evaluate your current Wegovy response, any tolerance issues, and specific clinical factors that might favour Mounjaro's dual-hormone approach. The dose escalation process must restart with Mounjaro's 2.5mg initial dose, regardless of your previous Wegovy maintenance level, as the medications have completely different pharmacokinetic profiles.
At EverydayMeds, our clinical team coordinates these transitions carefully, ensuring appropriate timing and monitoring throughout the changeover process. The decision to switch from Wegovy to Mounjaro often involves factors such as plateau in weight loss, persistent side effects, or specific clinical circumstances where the dual-hormone approach might offer advantages. However, many patients achieve excellent results with Wegovy long-term, making any medication change a carefully considered decision rather than a routine progression between treatments.
Your Next Steps: Accessing Both Wegovy and Mounjaro
EverydayMeds uniquely positions you to access both Wegovy and Mounjaro through a single trusted pharmacy, eliminating the need to research multiple suppliers or worry about treatment continuity. Start your journey with our 3-minute clinical assessment, using code FIRST40 for new customers or DOSE25 for returning patients at checkout. Our prescribers will evaluate your individual circumstances and recommend the most appropriate treatment option based on clinical evidence rather than marketing claims. Both treatments are available with next-day delivery once approved, backed by our GPhC-registered pharmacy credentials and commitment to pharmaceutical excellence. Whether you choose Wegovy's established GLP-1 approach or Mounjaro's dual-hormone mechanism, you'll receive ongoing clinical support throughout your weight management journey. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your assessment today and take the first step toward evidence-based weight management with either treatment option.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
